Portfolio Thuja Capital Healthcare Fund I
Cristal Therapeutics (formerly known as Cristal Delivery) is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies, registered as CriPec®. Cristal Delivery’s mission is optimise the therapeutic performance of drugs and thereby improve patient care.
TheraSolve develops a skin patch technology (embedded electronics) to improve drug treatment compliance.
Okapi develops antiviral drug products to treat viral diseases in pet animals and livestock. The company was acquired by Aratana Therapeutics Inc.
Fabpulous develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability (lateral flow). The first application is a rapid h-FAPB test as an aid in the early diagnosis of a heart infarct.
Bioceros is active in the field of protein therapeutics, and offers producer cell line generation services; it also aims to develop an own therapeutic monoclonal antibody pipeline. Our position was sold to a strategic investor.
argenx is monoclonal antibody company employing proprietory superior therapeutic antibody discovery platform to develop own antibody product portfolio.
DCPrime is a biotech company with a proprietary allogeneic dendritic cell line as a platform to derive and develop the next generation therapeutic dendritic cancer vaccines.
NightBalance is a medtech company developing and commercializing a patient-friendly device to treat positional sleep apnea.